Chandra Sorrelle
Acute Care · Phoenix, AZNPI 1538627914
Payments from drug & device makers
Across 834 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Mylan Specialty L.p.$1K
- Sanofi$875
- Boehringer Ingelheim$701
- plus $7K from 33 others
What the payments were for
- Food & beverage$15,68997%
- Education$5433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 86 | $3,009 |
| GSK | 197 | $2,390 |
| Actelion Pharmaceuticals US, Inc. | 60 | $1,414 |
| Mylan Specialty L.p. | 46 | $1,175 |
| Sanofi | 51 | $875 |
| Boehringer Ingelheim | 38 | $701 |
| Regeneron Healthcare Solutions, Inc. | 29 | $640 |
| Grifols USA, LLC | 37 | $585 |
| Paratek Pharmaceuticals, Inc. | 35 | $569 |
| Amgen | 25 | $439 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $405 |
| Genentech USA, Inc. | 23 | $375 |
| Baxter Healthcare | 19 | $332 |
| Electromed, Inc. | 28 | $324 |
| Mallinckrodt Hospital Products Inc. | 21 | $311 |
| United Therapeutics Corporation | 12 | $294 |
| Merck | 11 | $269 |
| ANI Pharmaceuticals, Inc. | 13 | $252 |
| Insmed, Inc. | 16 | $244 |
| Pulmonx Corporation | 5 | $218 |
| Advanced Respiratory, Inc | 11 | $181 |
| Verona Pharma, Inc. | 5 | $155 |
| Sanofi-aventis U.S. LLC | 2 | $146 |
| Teva Pharmaceuticals USA, Inc. | 7 | $134 |
| Novartis | 7 | $124 |
| Covis Pharma GmbH | 4 | $121 |
| Inspire Medical Systems, Inc. | 4 | $83 |
| Jazz Pharmaceuticals Inc. | 2 | $75 |
| Philips North America LLC | 3 | $68 |
| Bayer | 3 | $61 |
| ZOLL Respicardia, Inc. | 2 | $56 |
| Viatris Specialty LLC | 2 | $53 |
| Gilead | 2 | $44 |
| Johnson & Johnson | 2 | $29 |
| Shionogi Inc | 1 | $24 |
| Circassia Inc. | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$1,327
- TEZSPIRE$1,258
- BREZTRI$1,001
- AIRSUPRA$975
- SYMBICORT$463
- IMFINZI$266
- UPTRAVI$246
- OPSUMIT$246
- Yupelri$241
- CHARTIS CATHETER$159
- ZEPHYR DELIVERY CATHETER$159
- ZEPHYR ENDOBRONCHIAL VALVE$159
- PULMONX CHARTIS TABLET CONSOLE$159
- FARXIGA$155
- TRELEGY ELLIPTA$121
How this compares
$16,232 in reported general payments places this provider in the 95th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 46 | $583,075 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 395 | $481,365 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 32 | $435,375 |
| AdempasRiociguat | 17 | $240,642 |
| UptraviSelexipag | 12 | $220,549 |
| OfevNintedanib Esylate | 22 | $215,290 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 165 | $182,178 |
| Dupixent PenDupilumab | 33 | $122,874 |
| Breo ElliptaFluticasone/Vilanterol | 171 | $121,738 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 98 | $94,857 |
| Dupixent SyringeDupilumab | 26 | $93,692 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 86 | $71,591 |
| Advair HfaFluticasone Propion/Salmeterol | 98 | $64,309 |
| Spiriva RespimatTiotropium Bromide | 38 | $41,622 |
| SymbicortBudesonide/Formoterol Fumarate | 95 | $37,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,414 | $803,62458 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $2,390 | $696,999703 claims |
| Grifols USA, LLCProlastin C | $585 | $435,37532 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $701 | $351,768158 claims |
| BayerAdempas | $61 | $240,64217 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,009 | $219,647260 claims |
| MerckDulera | $269 | $13,79121 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $134 | $6,86814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 acute care providers in Arizona.
Other acute care in Phoenix
- Kim KrmpoticPhoenix$79K
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
- Nicole RauscherPhoenix$12K
- Brooke GambinoPhoenix$11K
- Kelly WesselhoffPhoenix$9K
- Jenna GonzalesPhoenix$8K
- Kristen HudsonPhoenix$8K
- Tammy TyreePhoenix$8K
- Lydia ChongPhoenix$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.